Abstract Body

Background

Cardiovascular (CVD)–kidney–metabolic (CKM) syndrome integrates overlapping risks of cardiovascular, metabolic, and kidney disease. Its pathophysiology is driven by chronic systemic inflammation and metabolic dysfunction, further amplified in people with HIV (PWH). Among people who inject drugs (PWID), the convergence of HIV and comorbidities may accelerate CKM progression. However, longitudinal CKM trajectories in PWH, particularly in PWID, are uncharacterized.

Methods

We analyzed data from the AIDS Linked to the IntraVenous Experience cohort, a prospective community cohort study of PWID in Baltimore, Maryland. CKM stages were defined according to the AHA framework, which categorizes individuals into: Stage 0 (no CKM risk factors), Stage 1 (excess and/or dysfunctional adiposity), Stage 2 (metabolic risk factors), Stage 3 (subclinical CVD or very high-risk CKD), and Stage 4 (clinical CVD or CKD). Due to small sample sizes, stages 3 and 4 were combined into stage 3+. We used multinomial mixed-effects logistic models to evaluate the association of HIV with CKM stage, and mixed-effects logistic models to evaluate progression over time. Models were adjusted for demographics, substance use, hepatitis C, and non-CKM comorbidities. Additional analyses examined the association by age, sex, viral load, and CD4 count.

Results

Among 1,771 participants (median age 48 [IQR: 42-54] years; 69% male; 78% black), most were classified as CKM stage 2 (78%), followed by stage 1 (13%). PWH were more likely to be in stage 2 (84% vs 75%) and stage 3+ (4% vs 1%; p<0.01). HIV was associated with a 10-fold higher burden of Stage 3+ (95% CI 4–24); with the highest burden for PWH with detectable viral load (RRR 12, 95% CI 5–32). Stage 3+ burden increased in both sexes, with no HIV×sex interaction. Predicted margins showed that people without HIV (PWoH) <50 years had the highest probability of remaining in Stage 0–1, while PWH ≥50 years were most likely to be in Stage 2 or Stage 3+ (Figure 1). At younger ages (<age 47), PWH progressed slower than PWoH; however, this trend reversed with age ≥47, with progressively increasing differences between PWH and PWoH (PInteraction <0.05; Figure 1).

Conclusions

PWH had a higher burden of advanced CKM and experienced more rapid progression with age. Apparent lower progression at younger ages was likely due to higher baseline CKM burden. As PWH age, integrating metabolic, cardiovascular, and kidney care with HIV care will be critical to reduce multimorbidity and mortality.

Table or Figure